Celeris Therapeutics is the pioneer in the AI-driven discovery of degraders against currently incurable diseases.Our innovative and patent-pending methods exploit the ubiquitin-proteasome system by predicting biomolecular interactions and ternary complexes and generating heterobifunctional and glue degrader molecules. Celeris One is a platform for Targeted Protein Degradation to collaborate with pharmaceutical and biotech companies. CelerisTx' drug pipeline, which is fully owned, addresses unmet medical needs.